EverSource Wealth Advisors LLC Has $433,000 Position in Merck & Co., Inc. (NYSE:MRK)

EverSource Wealth Advisors LLC grew its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 35.4% during the 1st quarter, HoldingsChannel reports. The firm owned 5,275 shares of the company’s stock after acquiring an additional 1,379 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $433,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Bromfield Sneider Wealth Advisors acquired a new stake in Merck & Co., Inc. during the first quarter worth about $79,000. Hikari Power Ltd grew its position in Merck & Co., Inc. by 5.0% during the first quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock worth $1,939,000 after buying an additional 1,130 shares in the last quarter. ACG Wealth grew its position in Merck & Co., Inc. by 5.6% during the first quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after buying an additional 722 shares in the last quarter. Mascoma Wealth Management LLC grew its position in Merck & Co., Inc. by 36.4% during the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock worth $76,000 after buying an additional 247 shares in the last quarter. Finally, WealthBridge Investment Counsel Inc. lifted its stake in Merck & Co., Inc. by 4.1% during the first quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company’s stock worth $7,206,000 after purchasing an additional 3,475 shares during the period. 73.33% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

MRK stock opened at $86.75 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. The company has a 50 day moving average price of $89.68 and a 200 day moving average price of $87.41. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $95.72. The stock has a market capitalization of $219.76 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 1.16 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm had revenue of $14.59 billion during the quarter, compared to analysts’ expectations of $13.85 billion. During the same quarter in the previous year, the company posted $1.31 EPS. Merck & Co., Inc.’s revenue was up 28.0% on a year-over-year basis. Analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Analyst Ratings Changes

A number of research analysts have commented on MRK shares. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Erste Group Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Mizuho started coverage on shares of Merck & Co., Inc. in a research note on Friday, June 24th. They set a “buy” rating and a $100.00 price target for the company. Daiwa Capital Markets upgraded shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and raised their price target for the stock from $89.00 to $102.00 in a research note on Wednesday, July 6th. Finally, Cowen raised their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.